Literature DB >> 8203357

Primary focal segmental glomerulosclerosis: clinical course and response to therapy.

S M Korbet1, M M Schwartz, E J Lewis.   

Abstract

Primary focal segmental glomerulosclerosis (FSGS) is a lesion associated with a poor prognosis and results in end-stage renal disease after 5 to 10 years. Based on past experience, many nephrologists have considered primary FSGS a lesion that is steroid resistant and therefore are reluctant to offer steroids as treatment. Recent data, however, have demonstrated that patients with primary FSGS have a response to steroid therapy that is considerably better than had been described. Thus, it may be that nephrologists have been more "steroid reluctant" than the lesion is steroid resistant. To better understand this issue we review the clinical course and response to therapy in patients with primary FSGS.

Entities:  

Mesh:

Year:  1994        PMID: 8203357     DOI: 10.1016/s0272-6386(12)80128-4

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  46 in total

Review 1.  Concurrent FSGS and Hodgkin's lymphoma: case report and literature review on the link between nephrotic glomerulopathies and hematological malignancies.

Authors:  Abdalla Mallouk; Phuong-Thu T Pham; Phuong-Chi T Pham
Journal:  Clin Exp Nephrol       Date:  2006-12-20       Impact factor: 2.801

2.  Treatment with Glucocorticoids or Calcineurin Inhibitors in Primary FSGS.

Authors:  Louis-Philippe Laurin; Adil M Gasim; Caroline J Poulton; Susan L Hogan; J Charles Jennette; Ronald J Falk; Bethany J Foster; Patrick H Nachman
Journal:  Clin J Am Soc Nephrol       Date:  2016-02-16       Impact factor: 8.237

3.  Long-term efficacy of low-density lipoprotein apheresis for focal and segmental glomerulosclerosis.

Authors:  Yukihiko Kawasaki; Sigeo Suzuki; Ayumi Matsumoto; Kei Takano; Kazuhide Suyama; Koichi Hashimoto; Junzo Suzuki; Hitoshi Suzuki; Mitsuaki Hosoya
Journal:  Pediatr Nephrol       Date:  2007-02-03       Impact factor: 3.714

4.  Dietary phthalates and low-grade albuminuria in US children and adolescents.

Authors:  Leonardo Trasande; Sheela Sathyanarayana; Howard Trachtman
Journal:  Clin J Am Soc Nephrol       Date:  2013-10-31       Impact factor: 8.237

Review 5.  [Minimal change disease and focal segmental glomerulosclerosis].

Authors:  J Müller-Deile; H Schenk; M Schiffer
Journal:  Internist (Berl)       Date:  2019-05       Impact factor: 0.743

6.  Thrombin-Induced Podocyte Injury Is Protease-Activated Receptor Dependent.

Authors:  Ruchika Sharma; Amanda P Waller; Shipra Agrawal; Katelyn J Wolfgang; Hiep Luu; Khurrum Shahzad; Berend Isermann; William E Smoyer; Marvin T Nieman; Bryce A Kerlin
Journal:  J Am Soc Nephrol       Date:  2017-04-19       Impact factor: 10.121

7.  Complete remission of nephrotic syndrome in an infant with focal segmental glomerulosclerosis: is it renin-angiotensin blockade?

Authors:  Neveen A Soliman; Magdi Francis; Saskia F Heeringa; Gil Chernin
Journal:  Pediatr Nephrol       Date:  2008-10-14       Impact factor: 3.714

Review 8.  Treatment of steroid-resistant nephrotic syndrome in the genomic era.

Authors:  Adam R Bensimhon; Anna E Williams; Rasheed A Gbadegesin
Journal:  Pediatr Nephrol       Date:  2018-10-02       Impact factor: 3.714

9.  Low-density lipoprotein apheresis in a pediatric patient with refractory nephrotic syndrome due to focal segmental glomerulosclerosis.

Authors:  Jun Oto; Kenichi Suga; Sato Matsuura; Shuji Kondo; Yoshiaki Ohnishi; Daisuke Inui; Hideaki Imanaka; Shoji Kagami; Masaji Nishimura
Journal:  J Anesth       Date:  2009-05-15       Impact factor: 2.078

10.  Mycophenolate mofetil in children with steroid/cyclophosphamide-resistant nephrotic syndrome.

Authors:  Valderez Raposo de Mello; Maira Tinte Rodrigues; Tais Helena Mastrocinque; Simone Paiva Laranjo Martins; Olberes Vitor Braga de Andrade; Eliana Biondi Medeiros Guidoni; Daniel Kashiwamura Scheffer; Dino Martini Filho; Julio Toporovski; Vanda Benini
Journal:  Pediatr Nephrol       Date:  2010-03       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.